Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: Comparison with amlopidine

Hypertension Research

Volumn 29, Issue 10, 2006, Pages 767-773

  Yamagishi, Toshio ^a  

^a TOHOKU ROSAI HOSPITAL   (Japan)

Author keywords

Azelnidipine; Home blood pressure; Home pulse rate; L type calcium channel blocker; Morning hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; AZELNIDIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HOME MONITORING; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MONOTHERAPY; OUTPATIENT CARE; PATIENT COMPLIANCE; PREDICTION; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SELF MONITORING; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AMLODIPINE; AZETIDINECARBOXYLIC ACID; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; CIRCADIAN RHYTHM; DIHYDROPYRIDINES; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PHYSICIANS' OFFICES;

EID: 33751578830     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.767     Document Type: Article

References (19)

1. Staessen JA, Wang JG, Thijs L: Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055-1076.
2. Ohkubo T, Imai Y, Tsuji I, et al: Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 1998; 16: 971-975.
3. Bobrie G, Chatellier G, Genes N, et al: Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-management in elderly treated hypertensive patients. JAMA 2004; 291: 1342-1349.
4. White WB: Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit 2001; 6: 63-72.
5. Gillman MW, Kannel WB, Belanger A, et al: Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993; 125: 1148-1154.
6. Hozawa A, Ohkubo T, Imai Y, et al: Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama Study. Am J Hypertens 2004; 17: 1005-1010.
7. Koike H, Kimura T, Kawasaki T, et al: Azelnidipine, a long-acting calcium channel blocker with slow onset and high vascular affinity. Annu Rep Sankyo Res Lab 2002; 54: 1-64.
8. Wellington K, Scott JL: Azelnidipine. Drugs 2003; 63: 2613-2621.
9. Kuramoto K, Ichikawa S, Hirai A, et al: Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003; 26: 201-208.
10. Imai Y, Otsuka K, Kawano Y, et al: Japanese Society of Hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res 2003; 26: 771-782.
11. Imai Y, Abe K, Sasaki S, et al: Clinical evaluation of semiautomatic and automatic devices for home blood pressure measurement: comparison between cuff-oscillometric and microphone methods. J Hypertens 1989; 7: 983-990.
12. Ishimitsu T, Kobayashi T, Matsuoka H, et al: Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients. Hypertens Res 2005; 28: 351-359.
13. Struck J, Muck P, Dodt C, et al: Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects. J Hypertens 2002; 20: 1143-1149.
14. Eguchi Y, Kario K, Shimada K: Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. Hypertens Res 2002; 25: 329-333.
15. Shokoji T, Fujisawa Y, Kiyomoto H, et al: Effect of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats. Hypertens Res 2005; 28: 1017-1023.
16. Kamoi K, Ikarashi T: The bedtime administration of doxazosin controls morning hypertension and albuminuria in patients with type-2 diabetes: evaluation using home-based blood pressure measurements. Clin Exp Hypertens 2005; 27: 369-374.
17. Kario K, Pickering TG, Umeda Y, et al: Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401-1406.
18. Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T: Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-α-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharm 2004; 43: 724-730.
19. Nakamura K, Yamagishi S, Inoue H: Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist. Med Hypotheses 2005; 65: 155-157.